Meeting
2022 ASCO Genitourinary Cancers Symposium
Quantifying absolute benefit of adjuvant treatments in renal cell carcinoma: A systematic review and network-meta-analysis.
Authors
Qurat Ul Ain Riaz Sipra
BUMC, Tucson, AZ
Qurat Ul Ain Riaz Sipra , Syed Arsalan Ahmed Naqvi , Mahnoor Islam , Noureen Asghar , Rabbia Siddiqi , Waleed Ikram , Parminder Singh , Wenxin Xu , Thai Huu Ho , Alan Haruo Bryce , Irbaz Bin Riaz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 360)
DOI
10.1200/JCO.2022.40.6_suppl.360
Abstract #
360
Poster Bd #
G7
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases.
First Author: İzzet Dogan
Poster
2020 Genitourinary Cancers Symposium
Cost-effectiveness of pembrolizumab in combination with axitinib as first-line treatment for advanced renal cell carcinoma.
First Author: Arielle G. Bensimon
Poster
2020 Genitourinary Cancers Symposium
Adjuvant therapy in high-risk renal cell cancer: A systematic review and cumulative meta-analysis.
First Author: Rabbia Siddiqi
Poster
2019 ASCO Annual Meeting
Meta-analysis of randomized clinical trials (RCT) for the adjuvant treatment of renal cell carcinoma (RCC) with vascular endothelial growth factor receptor tyrosine-kinase inhibitors (VEGFR TKIs).
First Author: Daniel Vargas Almeida